ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study.
<p><strong>INTRODUCTION:</strong> In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing-based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician-prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to...
Main Authors: | , , , , , , , , , , |
---|---|
Formato: | Conference item |
Publicado: |
Wiley
2019
|